Table of Contents
Executive Summary
- Defining cardiovascular risk
- Hypertension
- Dyslipidemia
- Diabetes
- Obesity
- Smoking cessation
Chapter 1 Defining cardiovascular risk
- Summary
- Introduction
- What is a risk factor?
- How do risk factors contribute to cardiovascular disease?
- Ethics and practicalities of preventive therapy
- Impact of an aging population
Chapter 2 Hypertension
- Summary
- Overview of hypertension
- Classification of hypertension
- Epidemiology
- Drug therapy
- Impact of ALLHAT study on anti-hypertensive therapy
- Results . generic diuretics should be first-line therapy
- Limitations of ALLHAT
- Support for greater ACE inhibitor use is strong
- ARBs will drive market growth
- Market analysis
- Norvasc (amlodipine)
- Cozaar/Hyzaar (losartan/losartan HCTZ)
- Diovan/Co-Diovan (valsartan/valsartan HCTZ)
- Avapro/Aprovel (irbesartan/irbesartan HCTZ)
- Outlook for the hypertension market
- Unmet needs
- Pipeline analysis
- Benicar (olmesartan)
- Inspra (eplerenone)
- Vanlev (omapatrilat)
- ALT-711
Chapter 3 Dyslipidemia
- Summary
- Overview of dyslipidemia
- Definition of dyslipidemia
- Markers for dyslipidemia
- Which markers are the best indicators of cardiovascular risk?
- Main types of dyslipidemia
- Hypercholesterolemia
- Familial hypercholesterolemia
- Hypertriglyceridemia
- Familial hypertriglyceridemia
- Mixed dyslipidemia
- Epidemiology
- Drug therapy
- Statins
- Fibrates
- Bile acid sequestrants/inhibitors
- Nicotinic acid derivatives
- Fish oil derivatives
- Market analysis
- Lipitor (atorvastatin)
- Zocor (simvastatin)
- Crestor (rosuvastatin)
- Zetia (ezetimibe)
- Outlook for the dyslipidemia market
- Unmet needs
- Pipeline analysis
- Livalo (pitavastatin)
- Caduet (atorvastatin + amlodipine)
Chapter 4 Diabetes
- Summary
- Overview of diabetes
- Pathophysiology and etiology
- Cardiovascular complications
- Mechanism of increased risk
- Epidemiology
- Diagnosing diabetes
- Drug therapy
- Sulfonylureas
- Biguanides
- Thiazolidinediones
- Prandial glucose regulators
- Alfa glucosidase inhibitors
- Insulins
- Monotherapy versus combination therapy
- Market analysis
- Avandia (rosiglitazone)
- Novolin (insulin)
- Humalog (insulin lispro)
- Lantus (insulin glargine)
- Outlook for the diabetes market
- Unmet needs
- Drug delivery
- Efficacy
- Side effects
- Awareness and education
- Glucose monitoring
- Pipeline analysis
- Exubera (inhaled insulin)
- AERx insulin Diabetes Management System (inhaled insulin)
- Oralin (transoral insulin)
- HIM2 (oral insulin)
Chapter 5 Obesity
- Summary
- Overview of obesity
- Definition of obesity
- Measuring and diagnosing obesity
- Pathophysiology and etiology
- Age and gender influence
- Genetic influence
- Nutritional influence
- Epidemiology
- Countering the trend . government action
- Drug therapy
- Market analysis
- Xenical (orlistat)
- Reductil/Meridia (sibutramine)
- Outlook for the obesity market
- Improving long-term drug safety
- Pipeline analysis
- Topamax (topiramate)
- Axokine
- P57
Chapter 6 Smoking cessation
- Summary
- Overview of smoking cessation
- Pathophysiology
- Epidemiology
- Drug therapy
- Market analysis
- Outlook for the smoking cessation market
- Unmet needs
- Pipeline analysis
- Zyban XL (bupropion)
- Rimonabant
- TA-NIC
- NicVAX
Chapter 7 Appendix
- References
- Index
List of Figures
- Figure 1.1: Cardiovascular risk factors
- Figure 1.2: Average annual growth rates of the total population and the
population in broad age
- groups, by major area, 2000-50 (median variant)
- Figure 2.3: Prevalence of hypertension in the seven major markets, 2002
- Figure 2.4: Timeline: the development of anti-hypertensive drug therapies
- Figure 2.5: Global anti-hypertensive market segmented by class, 2002
- Figure 2.6: Commercial opportunities in the treatment of hypertension
- Figure 3.7: Prevalence of hyperlipidemia in the major markets, 2002-10
- Figure 3.8: Timeline: the development of antidyslipidemic drug therapies
- Figure 4.9: Unmet needs in the treatment of diabetes
List of Tables
- Table 2.1: Classification and management of blood pressure for adults .
JNC 7 guidelines
- Table 2.2: Prevalence of hypertension in the seven major markets, 2002
- Table 2.3: Anti-hypertensive drug classes: summary of key facts
- Table 2.4: Anti-hypertensive drug classes: summary of key facts
(continued)
- Table 2.5: Sales of the top 10 anti-hypertensives, 2001-08
- Table 2.6: Selected hypertension pipeline, phase II and above, 2003
- Table 3.7: Prevalence of hyperlipidemia in the major markets, 2002-10
- Table 3.8: Selected leading and new antidyslipidemic product sales,
2001-08
- Table 3.9: The late-stage dyslipidemia pipeline, 2003
- Table 4.10: Prevalence of diabetes in the seven major markets, 2002
- Table 4.11: Leading and new diabetes product sales, 2001-08
- Table 4.12: Non-invasive insulin pipeline, 2003
- Table 5.13: Forecast prevalence of overweight or obese people in major
markets, 2001-08 (000s)
- Table 5.14: Current anti-obesity drugs
- Table 5.15: Leading anti-obesity product sales, 2001-08
- Table 5.16: The anti-obesity pipeline, phase II and above, 2003
- Table 6.17: Estimated smoking prevalence among men and women, 15 years of
age and over
- Table 6.18: Commonly used smoking cessation products
- Table 6.19: Smoking cessation Rx pipeline, 2003
|
Related Report
|
View Cart
